All News
#ACR22 Abstr#0823 A systematic review which included 36 case series/report showed pulmonary manifestations are common in #VEXAS 56%. Unclear if due to VEXAS or previous disease which was misclassified. Longitudinal study with accurate & timely diagnosis could help @RheumNow https://t.co/ZJvmK2FWrI
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Differentiation in UCTD? Abs 0328 finds puffy fingers, abnormal nailfold changes & SSc specific antibodies most predictive for UCTD progression to SSc. Younger age, serositis, +anti-dsDNA antibodies important for progression to SLE. #ACR22 @RheumNow https://t.co/DWL3V3dbFg https://t.co/fYHPOPdzfq
Dr. Rachel Tate uptoTate ( View Tweet)
Roongta et al. Small RCT of MTX+LEF vs MTX+RTX in RA. 21 patients each arm. No significant difference. @RheumNow #ACR22 Abstr#0931 https://t.co/jNDrMkkvhP https://t.co/dkfUnh5SM3
Richard Conway RichardPAConway ( View Tweet)
Sulli et al. Concommittent folic acid delays MTX response, leads to greater doses of steroids and MTX. But more AEs when MTX without folic acid 32 vs 16% - nausea, transaminase elevations. @RheumNow #ACR22 Abstr#0930 https://t.co/jsUYG2YIZL https://t.co/YOpUbA4Ze9
Richard Conway RichardPAConway ( View Tweet)
IL17i Ixekizumab IXE improved spinal pain at night (SpN) in AxSpA, COAST V 52 wk study
◦ improvement greatest with younger age, HLA-B27+, high disease activity at baseline
◦ associated with improved BASFI, fatigue, SF36
Ramiro S Abs1009 https://t.co/GiCqg7W9IR #ACR22 @RheumNow
Dr. Antoni Chan synovialjoints ( View Tweet)
Occupational inhaled agents increased risk of CCP+ RA, per Swedish occ data (OR 1.25, [1.12-1.38]). Dose-dependent increase in risk. Agents include quartz, asbestos, fungicides & carbon monoxide.
This is a common pt question!
@RheumNow ABST0601 #ACR22
https://t.co/QbsSLIXNar
Julian Segan JulianSegan ( View Tweet)
Park et al. MTX discontinuation for 1 week post-influenza vaccine non-inferior to 2 week hold. Higher flare rate with 2 week hold. @RheumNow #ACR22 Abstr#0936 https://t.co/G53mcWFK2C https://t.co/VFY9TS5OIv
Richard Conway RichardPAConway ( View Tweet)
Ab409 #ACR22 Bimekizumab (IL17A, IL17F) & PROs
P Mease on BE MOBILE 1 & 2
BKZ 160 mg q4w vs PBO
254 pts w nr-axSpA, 332 w AS
Improvement in spinal pain, nocturnal pain, morning stiffness, FACIT-FATIGUE for pts with AS and nr-axSpA, statistically signif diff at WK 16
@RheumNow https://t.co/nxZFSrb2XK
Eric Dein ericdeinmd ( View Tweet)
Ab1044 #ACR22 Combined Biologic or Targeted Therapy (CBTT) in SpA
31 CBTT courses in 29 SpA pts - 69% also w IBD
Most common: TNF+IL12/23 or IL17
12 pts (38%) d/c CBTT - 7 inefficacy (5 2/2 IBD), 2 for AEs, 3 for other causes. 2 serious AEs (pulm infiltrates, staph ifn)
@RheumNow https://t.co/zExkpam0zK
Eric Dein ericdeinmd ( View Tweet)
Reid et al. Safety of immune checkpoint inhibitor combo vs mono in pre-existing autoimmune disease. No significant difference. But 59% vs 32% for irAEs and 23% vs 10% for high grade irAEs @RheumNow #ACR22 Abstr#0757 https://t.co/UYhRM4xO9r https://t.co/r4NurxXzGZ
Richard Conway RichardPAConway ( View Tweet)
Bilal et al. Increased risk VTE in aPL+ SLE patients on estrogen vs progesterone contraceptive. All forms progesterone appears equally safe (differs ACR guidance which does not recommended IM or implant) @RheumNow #ACR22 Abstr#0943 https://t.co/HGuZJgaRZQ https://t.co/KrIaKaYNTy
Richard Conway RichardPAConway ( View Tweet)
7pm ET on 11/13, join our SLE panel. #ACR22
https://t.co/B8XdaJFLS2 https://t.co/kqJRI2QRms
Links:
Dr. John Cush RheumNow ( View Tweet)
It's brilliant lab work @MayoClinic that had led the way for JAKi in GCA in clinical trials.
A compelling bench-to-bedside story by @MdWarrington, Dr. Weyand, Dr. Koster and team, and definitely a space to watch
#ACR22 @RheumNow https://t.co/2acKFrWOUF
David Liew drdavidliew ( View Tweet)
"You won't find IgG4-RD anywhere [in the 2012 Chapel Hill nomenclature], but it is absolutely a vasculitis"
-John Stone
#ACR22 @RheumNow
Mike Putman EBRheum ( View Tweet)
LILAC study abstracts 0364 and 0365 SLE pts w/ joint and skin activity treated with BIIB059 had consistent improvements vs PBO. More to come! #ACR22 @RheumNow https://t.co/WPl3tol7v9 and https://t.co/8cyrI3W9rD https://t.co/5W4KMOHHEA
Links:
Dr. Rachel Tate uptoTate ( View Tweet)
Need to know! Wigley says ‘each organ system has unique properties’ so ex Rx of skin may not help vasculopathy or #SSc renal crisis Rx is ACEi vs CCB in #Raynauds. 1 drug won’t be sufficient in complex diseases #13S114 #ACR22 #ACRBest @RheumNow #ClinicalPearl https://t.co/S8fHi7dFoD
Janet Pope Janetbirdope ( View Tweet)
MoA qu in GCA:
Is one JAKi better?
lab in tofa
proof-of-concept in bari
clinical trial in upa
@MdWarrington: unclear if any diff clinically
GM-CSF vs IL-17?
Maria Cid: lots of redundancy in immune system
blocking one pathway, escalation of another?
we will see
#ACR22 @RheumNow
David Liew drdavidliew ( View Tweet)
Combined pulmonary HTN and ILD seen in 7% in large scleroderma database. Unsurprisingly, survival worse then PAH/ILD alone. HAQ also worse in this group.
@RheumNow @earlyARA #ACR22 ABST1058
https://t.co/Jr58wVLC31 https://t.co/UCjKuJB1ev
Julian Segan JulianSegan ( View Tweet)
Abs 0359 TULIP-1&2 data showed nearly 10% of anifrolumab-treated pts achieved remission, suggesting that DORIS response is attainable. #ACR22 @RheumNow https://t.co/laPwd0KpSa https://t.co/6LZ1WLrc97
Dr. Rachel Tate uptoTate ( View Tweet)
Great scientific talk by John Stone, IgG4-RD should be a considered a variable-vessel disease, much like Behcet's and Cogan's syndrome
I had not viewed it from that perspective; adding it to the list! Series of patietns w/coronary involvement esp interesting
#ACR22 @RheumNow https://t.co/JUayLOTnSB
Mike Putman EBRheum ( View Tweet)